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Purpose: Family history is associated with gliomas, but this association has not been
established for benign brain tumors. Using information from newly diagnosed primary brain
tumor patients, we describe patterns of family cancer histories in patients with benign brain
tumors and compare those to patients with gliomas. Methods: Newly diagnosed primary
brain tumor patients were identiﬁed as part of the Ohio BrainTumor Study. Each patient was
asked to participate in a telephone interview about personal medical history, family history
of cancer, and other exposures. Informationwas available from33 acoustic neuroma (65%),
78 meningioma (65%), 49 pituitary adenoma (73.1%), and 152 glioma patients (58.2%).
The association between family history of cancer and each subtype was compared with
gliomas using unconditional logistic regression models generating odds ratios (ORs) and
95% conﬁdence intervals. Results:There was no signiﬁcant difference in family history of
cancer between patients with glioma and benign subtypes. Conclusion:The results sug-
gest that benign brain tumor may have an association with family history of cancer. More
studies are warranted to disentangle the potential genetic and/or environmental causes
for these diseases.
Keywords: meningioma, acoustic neuroma, pituitary tumor, glioma, family history of cancer
INTRODUCTION
The overall incidence of benign and malignant brain tumors is
18.71 per 100,000 person years; 11.52 per 100,000 person years
for benign tumors; and 7.19 per 100,000 person years for malig-
nant tumors (CBTRUS, 2010). The most common benign brain
tumor in adults is meningioma, followed by pituitary adenoma,
and acoustic neuroma (also called schwannoma). A small pro-
portion of meningiomas (6–8%) are World Health Organization
(WHO) grade II or grade III (Wrobel et al., 2005). Otherwise,
all benign tumors are considered to be WHO grade I. The most
common primary malignant brain tumors are gliomas, the most
common of which is glioblastoma multiforme (GBM), a WHO
grade IV tumor (CBTRUS, 2010).
The only established environmental risk factor for gliomas and
meningiomas is ionizing radiation exposure to the head and neck;
allergies have been inversely associated with glioma risk (Wren-
sch et al., 2002; Ohgaki and Kleihues, 2005; Barnholtz-Sloan and
Kruchko, 2007; Bondy et al., 2008). Inherited syndromes such as
neuroﬁbromatosis 1 and 2, tuberous sclerosis, Li-Fraumeni syn-
drome, and Turcot syndrome can also increase one’s and one’s
family members’ risk for bothmalignant and benign brain tumors
aswell as for other cancers (Louis and vonDeimling, 1995;Malmer
et al., 2005). In addition,multiple studies have shown an increased
risk of brain tumors and other cancers for family members of spo-
radic glioma or meningioma patients (Hemminki et al., 2001; Hill
et al., 2003, 2004).
www.frontiersin.org February 2012 | Volume 2 | Article 19 | 1
Ostrom et al. Family history of cancer in brain tumors
While many studies have established an association between
family history of cancer and glioma, few have assessed patterns of
family history of cancer in benign brain tumor subtypes (Bondy
et al., 2008; McCarthy et al., 2011). The relationship between
glioma and family history of cancer has been explored by several
investigators, and family history of malignancy has been estab-
lished as a risk factor for gliomas (Hemminki et al., 2000, 2001,
2007; Hemminki and Li, 2004). The studies that have looked into
benign brain tumor subtypes primarily focus on meningioma
and/or acoustic neuroma only, and while some have shown signif-
icant associations between family history of cancer and increased
odds of a brain tumor, others have shown no association (Sakas
et al., 1994; Louis and von Deimling, 1995; Maxwell et al., 1998;
Hemminki et al., 2000, 2001; King and Gutmann, 2000; Hill et al.,
2003, 2004; Malmer et al., 2003; Bacci et al., 2010).
While studies have utilized large databases to assess family his-
tory of cancer as a potential risk factor for some benign brain
tumor types, most have just examined family history of speciﬁc
cancer types, such as brain tumors or other central nervous system
tumors. No prior studies could be identiﬁed that examine differ-
ences in family history of cancer between benign primary brain
tumors and gliomas. No previous study has established family
history of cancer as a risk factor for benin brain tumors, though
they have suggested associations between benign brain tumors
and some speciﬁc cancer types. Because a family history of malig-
nancy has been previously established as a risk factor for gliomas
(Hemminki et al., 2000, 2001, 2007; Hemminki and Li, 2004) our
study uses a group of patients with glioma as a reference group to
establish whether family history of cancer may be associated with
benign brain tumor types, using information from newly diag-
nosed primary brain tumor patients enrolled in a multi-site study
within Ohio.
MATERIALS AND METHODS
THE OHIO BRAIN TUMOR STUDY
The Ohio Brain Tumor Study (OBTS) is a multi-site study in
Ohio that prospectively accrues newly diagnosed, untreated brain
tumor patients. This network is comprised of four major acade-
mic brain tumor centers in the state of Ohio: The Brain Tumor
and Neuro-Oncology Center at University Hospitals CaseMedical
Center (UHCMC) the clinical afﬁliate of the CaseWestern Reserve
University (CWRU) School of Medicine, the Rose Ella Burkhardt
Brain Tumor and Neuro-Oncology Center at the Cleveland Clinic
(CC), The Dardinger Neuro-Oncology Center, Department of
Neurosurgery at the James Cancer Hospital and the Ohio State
University Medical Center (OSU) and the Brain Tumor Center
at the University of Cincinnati (UC). All newly diagnosed pri-
mary brain tumor patients are identiﬁed at each center by research
nurses, and informed consent is obtained. Patients that have been
diagnosed with a familial cancer syndrome are excluded. From
each the following are obtained: blood sample, snap-frozen tumor
tissue within 30min of resection, and/or re-cuts of formalin-
ﬁxed, parafﬁn embedded (FFPE) tumor tissue (for histopathology
review), interview/questionnaire data, medical chart review, and
active yearly follow-up for clinical outcomes. All sites have their
own IRB approvals and use the same standardized study protocol,
procedures, and informed consent. In addition each OBTS site
has a fully executed Research/Material Transfer Agreement with
CWRU.
QUESTIONNAIRE AND VARIABLES OF INTEREST
Each subject is asked to take part in a telephone interview last-
ing 30–45min. The interview uses a standardized questionnaire
for all patients that includes questions regarding subjects’ med-
ical history, family history of cancer, medication history, tobacco
use, and other environmental exposure history (potential expo-
sures they may have been exposed to during work or hobbies). All
patients are administered the same questionnaire, and all ques-
tionnaire interviews for all sites are performed by the CWRU
research staff. If the patient is unable to complete the question-
naire, a proxy is allowed to complete the interview. To limit recall
bias, interviews are conducted shortly after completion of surgery
and neoadjuvant treatment. Clinical variables, such as type of
tumor (meningioma, acoustic neuroma, pituitary, astrocytoma,
oligodendroglioma, oligoastrocytoma), andWHO grade of tumor
(I, II, III, IV), were abstracted from patient medical records. Fam-
ily history of cancer information was not conﬁrmed via clinical
records.
The questionnaires are constructed to elicit the following vari-
ables of interest: age at diagnosis, gender, and detailed family
history of cancer. Due to small sample sizes of oligodendrogliomas
and oligoastrocytomas, these subtypes were grouped with astro-
cytomas into “gliomas” for analysis, and due to small sample sizes
of atypical and anaplastic meningiomas, i.e., grade II and III, all
meningiomas were analyzed together as a single group. Family his-
tory of cancer was coded as a four level variable: none, ﬁrst-degree
only, second-degree only, and ﬁrst and second-degree. The type of
relative and type of cancer that the relative had were also recorded
for all relatives.
STATISTICAL ANALYSIS
Frequency and proportions were calculated for all variables of
interest and categorized by tumor subtypes. Chi-square and
Fisher’s exact tests were used to test for differences in key vari-
ables of interest within each subtype classiﬁcation. The association
between family history of cancer (none, ﬁrst-degree only, second-
degree only, and ﬁrst and second-degree, and by speciﬁc cancer
types) and each benign subtype as compared to gliomas was mod-
eled using an unconditional logistic regression model generating
odds ratios (ORs) and 95% conﬁdence intervals (95% CI). Logis-
tic regression models were compared to the Base model, which
included the adjustment factors only, using a likelihood ratio test
(LRT) generating a two-sided p-value.
RESULTS
Initially, 494 subjects that met histological criteria were consented
for OBTS and follow-up interviews were completed with 312
(63.2% overall; Table 1). The highest proportion of interviews
were obtained from patients with pituitary tumors (73.1% over-
all). Themajority of benign brain tumor patients were female, and
had an average age at diagnosis of 54 years. Interestingly, 20.5% of
patients with meningiomas and 22.4% of patients with pituitary
tumors were non-white as compared to 0% of acoustic neuroma
patients (Fisher’s exact p-value= 0.004; Table 1). Eighty-six per-
cent of meningiomas were grade I tumors. Themajority of glioma
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Table 1 | Characteristics of OBTS study population.
Benign subtypes Gliomas
Meningioma Acoustic
neuroma
Pituitary
adenoma
p-Valuea Astrocytoma Oligo-
dendroglioma
Oligo-
astrocytoma
p-Valueb
Total consented 120 46 67 223 27 11
Total interviewedc 78 65.0% 33 71.7% 49 73.1% 131 58.7% 16 59.3% 5 45.5%
Interview type Proband 76 97.44% 32 96.97% 49 100.0% 96 73.28% 16 100.0% 4 80%
Proxy 2 2.66% 1 3.03% 0 0.0% 35 26.72% 0 0.0% 1 20%
Gender Male 27 34.6% 17 51.5% 22 44.9% 0.2101 77 58.8% 12 75.0% 2 40.0% 0.3321d
Female 51 65.4% 16 48.5% 27 55.1% 54 41.2% 4 25.0% 3 60.0%
Race White 62 79.5% 33 100% 38 77.6% 0.0039d 120 91.6% 15 93.8% 5 100.0% 1.0000d
Black/other 16 20.5% 0 0% 11 22.4% 11 8.4% 1 6.3% 0 0.0%
Mean age at diagnosis
(minimum, maximum)
55 (22–85) 53 (31–75) 53 (29–75) 57 (20–92) 43 (28–66) 47 (19–65)
Histology Grade I 67 85.9% 33 100.0% 0 0.0% 1 0.8% 0 0.0% 0 0.0%
Grade II 10 12.8% 0 0.0% 0 0.0% 10 7.6% 9 56.3% 3 60.0%
Grade III 1 1.3% 0 0.0% 0 0.0% 13 9.9% 6 37.5% 2 40.0%
Grade IV 0 0.0% 0 0.0% 0 0.0% 105 80.2% 0 0.0% 0 0.0%
No grade 0 0.0% 0 0.0% 49 100.0% 0 0.0% 0 0.0% 0 0.0%
aMeasures signiﬁcance of difference between the benign brain tumor subtypes for distribution of this variable.
bMeasures signiﬁcance of difference between the glial brain tumor subtypes for distribution of this variable.
cSome participants declined to provide family history. This population is used for calculating the percentages in the rest of the table.
dFisher’s exact test.
patients were male, white, and had an average age at diagnosis of
55.2 years (Table 1). The majority of gliomas were glioblastomas
(Table 1).
Of the 312 patients interviewed, 74.68% reported a ﬁrst or
second-degree family history of cancer (Table 2). Those with
a pituitary adenoma reported the highest proportion of family
history of cancer (81.63%). In comparison, this proportion was
75.64% for the meningiomas, 75.76% for the acoustic neuromas,
and 71.71% for the gliomas (Table 2). Overall, 56% of patients
reported at least one ﬁrst-degree relative with cancer. Proportions
with ﬁrst-degree history of cancer were 58.98% for meningioma
patients, 45.45% for acoustic neuroma patients, 51.02% for pitu-
itary adenoma patients, and 57.89% for glioma patients. Notably,
there are high proportions of colorectal cancers and nervous sys-
tem cancers across all subtypes. Overall, the most common cancer
types in this population’s family members were lung, colorectal,
breast, prostate, and brain.
Comparisons between each of the benign brain tumor types
and gliomas showed that for patientswith benign subtypes, there is
no difference in the odds of having a ﬁrst-degree or second-degree
relative with cancer. Patients with meningioma had decreased
odds of having a ﬁrst-degree relative with breast cancer compared
to glioma patients after adjustment for age at diagnosis, gender,
family size, and race [OR= 0.225, 95% CI (0.059–0.857), LRT
p-value= 0.082; Table 3].
DISCUSSION
The population accrued by the OBTS and the subpopulation
included in this analysis are demographically similar to the broader
US population of brain tumor patients, with our subpopulation
being 50.32% male and 87.5% white (Table 1). The Central Brain
TumorRegistry of theUS (CBTRUS)was 43.11%male and84.81%
white (CBTRUS, 2010). Of note are the relatively high propor-
tions of non-white meningioma and pituitary patients in the
OBTS population. The CBTRUS data also show a higher inci-
dence of meningiomas and pituitary tumors and a lower incidence
of gliomas in blacks as we observed in our OBTS study popu-
lation. US population-based data show a female dominance for
meningiomas, as we had in the OBTS study (CBTRUS, 2010). The
similarities between the OBTS population and that reported in
CBTRUS suggest that brain tumor patient population sharesmany
demographic characteristics with the United States population
with brain tumor at large.
The overall proportions of family history of cancer in this pop-
ulation are high when compared to previous studies of the general
population (Ramsey et al., 2006) and the proportionof ﬁrst-degree
family history of cancer in this population is comparable to that
found in a hospital-based study of malignant brain tumor patient
populations (Scheurer et al., 2007). Previous registry and case
control studies have found an elevated risk for speciﬁc cancers
particularly nervous system cancers (Hemminki et al., 2000, 2001;
Malmer et al., 2003),or family history of cancer in ﬁrst-degree rela-
tives of personswithmeningioma (Hill et al., 2004).A family study
conducted by Sakas et al. (1994) found no signiﬁcant difference in
family history of cancer betweenpersonswith benign ormalignant
brain neoplasms and healthy controls. Our population reported
relatively high rates of nervous system cancers in ﬁrst and second-
degree relatives, compared to previous studies that have suggested
elevated standard incidence ratios for nervous systems in ﬁrst-
degree family members of persons with meningioma (Hemminki
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Table 2 | Overall and site-specific family history of cancer by brain tumor histologic type.
Cancer site Degree of relative
with cancer
Meningioma
(n=78)
Acoustic neuroma
(n=33)
Pituitary adenoma
(n=49)
All gliomas
(n=152)
Overall None 19 24.36% 8 24.24% 9 18.37% 43 28.29%
1˚ 22 28.21% 7 21.21% 13 26.53% 58 38.16%
2˚ 13 16.67% 10 30.30% 15 30.61% 21 13.82%
1˚ and 2˚ 24 30.77% 8 24.24% 12 24.49% 30 19.74%
Breast None 67 85.90% 26 78.79% 34 69.39% 119 78.29%
1˚ 3 3.85% 3 9.09% 6 12.24% 18 11.84%
2˚ 6 7.69% 4 12.12% 8 16.33% 11 7.24%
1˚ and 2˚ 2 2.56% 0 0.00% 1 2.04% 4 2.63%
Colon None 65 83.33% 29 87.88% 40 81.63% 143 94.08%
1˚ 8 10.26% 1 3.03% 2 4.08% 6 3.95%
2˚ 4 5.13% 3 9.09% 6 12.24% 3 1.97%
1˚ and 2˚ 1 1.28% 0 0.00% 1 2.04% 0 0.00%
Prostate None 69 88.46% 28 84.85% 41 83.67% 138 90.79%
1˚ 2 2.56% 4 12.12% 2 4.08% 11 7.24%
2˚ 7 8.97% 1 3.03% 4 8.16% 3 1.97%
1˚ and 2˚ 0 0.00% 0 0.00% 1 2.04% 0 0.00%
Lung None 59 75.64% 25 75.76% 36 73.47% 116 76.32%
1˚ 9 11.54% 2 6.06% 3 6.12% 24 15.79%
2˚ 9 11.54% 5 15.15% 10 20.41% 12 7.89%
1˚ and 2˚ 1 1.28% 1 3.03% 0 0.00% 0 0.00%
Brain None 66 84.62% 29 87.88% 40 81.63% 132 86.84%
1˚ 6 7.69% 0 0.00% 2 4.08% 13 8.55%
2˚ 6 7.69% 3 9.09% 7 14.29% 7 4.61%
1˚ and 2˚ 0 0.00% 1 3.03% 0 0.00% 0 0.00%
and Li, 2004). Previous studies have not compared benign brain
tumor populations to brain tumor populations where family his-
tory of cancer is a established risk factor. Previous studies have
largely not examined overall family history of cancer, but rather
have focused on speciﬁc cancer types.
Both case control and registry-based studies have suggested
an association between breast cancer (or a family history of breast
cancer) and eithermeningiomas or pituitary adenomas (Hill et al.,
2004; Hemminki et al., 2007).We found decreased odds of having
a ﬁrst-degree relative with breast cancer for meningioma patients,
as compared to all glioma patients. Our data do not show that
either pituitary adenoma or acoustic neuroma has a statistically
greater or lesser likelihood of having a relative with breast cancer.
Hemminki et al. (2007) showed an association between patients
with pituitary adenoma and siblings with colorectal and breast
cancer, as well as other tumor types, in a study based on validated
registry data.
TheOBTS accrues newly diagnosed primary benign andmalig-
nant brain tumor patients from four large tertiary referral centers
in Ohio. Recruiting from tertiary care centers allows the OBTS to
recruit a higher proportion of higher grade andmalignant tumors,
while recruiting less low grade and non-malignant tumors. A stan-
dardized protocol for screening,patient accrual anddata collection
is used at all participating sites. Telephone interviews and medical
chart reviews are done centrally by staff from CWRU, using a
regular study staff that has all completed the same standardized
training to minimize bias. Though the sample size of this analysis
is considerable considering the rarity of brain tumors, the small
sample size results in some instability of the data produced by
the analysis. Previous studies that have examined the relation-
ship between family history and brain tumors have been based
on populations between 3239 and 11,875 in registry-based studies
(Malmer et al., 2003; Hemminki et al., 2007), 96 in case control
studies (Hill et al., 2004), and 142 in family-based studies (Sakas
et al., 1994). Previous studies examining the relationship between
family history of cancer and glioma have been based on popula-
tions between 462 and 489 in case control studies (Wrensch et al.,
1997; Hill et al., 2003), 20358 in registry-based studies (Malmer
et al., 2003), and between 639 and 1476 in family-based studies (de
Andrade et al., 2001; Scheurer et al., 2007). The population used in
this analysis is on the lower end of this spectrum,but is comparable
to previous studies. Accrual of additional patients over time will
improve the power to detect associations. A similar analysis with
registry data that contains clinically validated family history data
would also build upon the correlation suggested by this analysis.
Usingpatientswith gliomas as a comparison grouppresents sig-
niﬁcant limitations for the results of this analysis.While an analysis
using a control group of persons without brain tumor would pro-
duce more generalizable data about risk of benign brain tumor
based on family history of cancer, using a reference group known
to have an increased risk of family history of cancer also provides
an informative comparison. Though this does not establish fam-
ily history of a cancer as a risk factor for benign brain tumors, it
does suggest that there may be some association between the two
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when compared to persons with glioma that are known to have an
increased risk of family history of cancer. Future comparison of
this benign brain tumor population with healthy controls would
provide more information about family history of cancer as a risk
factor for benign brain tumors. Additionally, there may be other
potential factors that may be related to increased family history of
cancer were not included in this analysis.
All of the family history data used in the current analysis were
collected from patient self-report via telephone interview with
a standardized questionnaire, where only 3% of the interviewed
population chose not to answer questions about their family
history of cancer. Though family history information was not vali-
dated using medical records, previous studies have concluded that
subjects are able to accurately report the cancer history of fam-
ily members without observable bias, but that cancer site-speciﬁc
recall may be less accurate than recall of whether a cancer his-
tory exists (Kerber and Slattery, 1997; Airewele et al., 1998). Even
with cancer site-speciﬁc recall difﬁculties, researchers have found
that ﬁrst-degree relative cancer history is reported at 83% accu-
racy, and second-degree relative cancer history is reported at 67%
(Love et al., 1985). Mai et al. (2011) found that site-speciﬁc recall
may generally be less accurate than this, ﬁnding positive predictive
values of 40% for lung cancer, 53.5% for colorectal cancer, 61.3%
for breast cancer, and 53.4% for prostate cancer, with reporting
on ﬁrst-degree relatives being signiﬁcantly more accurate than
second-degree relatives. Thus the information about whether a
family cancer exists collected via the questionnaire is assumed to
be largely accurate, although the site-speciﬁc information may be
less dependable. The study design of the OBTS consorsium does
not currently allow for validation of family cancer history data via
family medical records, though this would improve the validity
generalizability of this analysis. This difference between odds for
ﬁrst-degree versus second-degree relatives may be a result of the
decreased reliability of patient self-report of second-degree rel-
ative cancer history. In addition, the site-speciﬁc ORs may have
occurred by chance due to the lack of reliability of site-speciﬁc
self-report of family history of cancer.
Some patients in the OBTS study died before the interview was
initiated or were otherwise lost to follow-up, and others declined
to participate in the interview after initial consent. Participation
was particularly low among patients with astrocytomas, oligo-
dendrogliomas, and oligoastrocytomas (58.75, 59.3, and 45.5%
interview participation, respectively). We surmise that this might
reﬂect the additional stresses these patients were subjected to due
to the need for adjuvant therapies that was uncommon in the other
groups, though this was not quantiﬁed. This may also represent a
survival bias, as persons that died shortly after or during surgery
or treatment were excluded from this analysis. Median survival for
persons with glioma who were not interviewed versus those who
were interviewed was signiﬁcantly different, with median survival
Table 5 | Characteristics of interviewed and non-interviewed patients.
Interviewed Not interviewed p-Value
Male 157 50.32% 93 51.10% 0.8674
White 273 87.50% 156 85.71% 0.5711
Median age (minimum, maximum) 55 (19, 92) 56 (21, 86) 0.5111
Mean survival (95% CI; days) All gliomas 190 (152–307) 523 (406–689) <0.001
Histologic type Acoustic neuroma 33 100% 13 100%
Meningioma
Grade I 67 85.90% 25 64.10% 0.0067
Grade II–III 11 14.10% 14 35.90%
Pituitary adenoma 49 100% 18 100%
Astrocytoma 0.6345a
Grade I 1 0.78% 2 2.22%
Grade II 10 7.75% 10 11.11%
Grade III 13 10.08% 7 7.78%
Grade IV 105 81.40% 71 78.89%
Oligoastrocytoma 1.0000a
Grade II 3 60.00% 4 66.67%
Grade III 2 40.00% 2 33.33%
Oligodendroglioma 0.3945a
Grade II 9 60.00% 9 81.82%
Grade III 6 40.00% 2 18.18%
Grade No grade 49 15.86% 18 10.17% 0.0047
Grade I 101 32.69% 40 22.60%
Grade II 32 10.36% 35 19.77%
Grade III 22 7.12% 13 7.34%
Grade IV 105 33.98% 71 40.11%
aFisher exact test.
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of 190 days (95% CI 152–307) and 523 days (95% CI 406–689)
respectively (p< 0.001). Overall, our response rate was very good
when compared to other survey or questionnaire-based studies.
A particular strength is the structured interview, which may have
allowed us to better elicit family history data.
When a patientwas unable to complete the telephone interview,
a proxy was allowed to complete the interview on behalf of that
patient. Rates of proxy interview were relatively low in the benign
tumor types (3.03% for acoustic neuromas, 2.66% for menin-
giomas, and 0% for pituitary tumors;Table 1). In the glioma types,
rates were higher, particularly in the astrocytomas and oligoastro-
cytomas (rates of proxy interviewwere 26.72 and 20%respectively;
Table 1). When these proxy interviews were excluded from the
analysis, the effects detected in the overall comparison remained
(Table 4).
The population that consented to the study but did not partic-
ipate in the interview had no statistically signiﬁcant difference in
gender, race, or age, with the population that completed the inter-
view (Table 5). However, among meningioma patients, the un-
interviewed population had a signiﬁcantly increased proportion
of higher grade tumors (14.10% grade II or III in the interviewed
population and 35.90%grade II or III in the un-interviewed popu-
lation, p = 0.0067; Table 2). There was no signiﬁcant difference in
the proportion of grades in the astrocytoma (81.4%grade IV in the
interviewed population and 78.9% grade IV in the un-interviewed
population), oligodendroglioma (40% grade III in the interviewed
population and 33.39% grade III in the un-interviewed popu-
lation), or oligoastrocytoma (40% grade III in the interviewed
population and 18.9% grade III in the un-interviewed popu-
lation) patients (Table 5). As this study involves patients who
may be very ill and have signiﬁcant neurocognitive problems, an
overall interview rate of 63.16% is considered high. Because of
the small sample size of atypical meningiomas, all meningiomas
were grouped together for analysis. In addition, all gliomas were
grouped together for analysis regardless of subtype because of the
small number of non-astrocytic gliomas. Therefore, our menin-
gioma results could be biased toward grade I meningiomas and
our glioma results could be biased toward glioblastomas. Glioblas-
toma only comparisons still showed signiﬁcantly increased odds of
patients with pituitary adenomas having a second-degree relative
with cancer.
In conclusion, the odds of having a ﬁrst or second-degree rela-
tive with cancer are not signiﬁcantly different between patients
with benign tumors and patients with gliomas. As previous
research has established an association between family history of
cancer and gliomas, this suggests that it may also be associated
with benign brain tumors. Previous research has not established
family history of cancer as a risk factor for benign brain tumors,
and have produced some conﬂicting results. Our study and others
suggest that more family studies of brain tumor subtypes are war-
ranted to disentangle the potential genetic and/or environmental
causes for familial occurrence of these neoplasms.
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